All Posts Tagged With: "RDEA"
(RDEA) Ardea Biosciences – Bull of the Day
We are upgrading Ardea Biosciences Inc (RDEA) to Outperform from Neutral due to the promise shown by its lead pipeline candidate lesinurad, which is being developed for treating hyperuricemia and gout. Lesinurad,...
(RDEA) Ardea Biosciences Analyst Maintains Neutral Rating
We are maintaining our Neutral recommendation on Ardea Biosciences Inc. (RDEA) with a target price of $20.
Ardea Biosciences, headquartered in San Diego, CA, focuses on the discovery and development...
(SVNT) Savient Pharmaceuticals Announces the FDA accepted Biologics License Application
Recently, Savient Pharmaceuticals, Inc. (SVNT) announced that the U.S. Food and Drug Administration (FDA) accepted...
(RDEA) Ardea Biosciences Sees Good News
Recently, Ardea Biosciences, Inc. (RDEA) announced positive results from the first dosing group of a one-week randomized, placebo-controlled drug-combination study in normal healthy volunteers of its candidate...
(RDEA) Ardea Biosciences Inc. Lowers Loss
Ardea Biosciences Inc. (RDEA) reported third quarter net loss of $2.47 million, or 13 cents per share, which was significantly lower than the Zacks Consensus Estimate of 47 cents. The company reported a net...
(SVNT) Savient Pharmaceuticals Gout Drug Trials Suspended
Savient Pharmaceuticals Inc. (SVNT), after meeting officials from the U.S. Food and Drug Administration (FDA) on Monday, announced that the agency does not expect further clinical trials to be conducted for its gout drug Krystexxa, as the company has now...